Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen
In another sign that China’s up-and-coming biotech community continues to gather steam, an upstart called EpimAb Biotherapeutics has hauled in a $25 million A round to go after clinical studies for its bispecific antibodies designed for immuno-oncology.
EpimAb is another example of a local Shanghai company with global roots. Its CEO is Chengbin Wu, a Harvard postdoc who had worked at Abbott before being named CSO at Shanghai CP Guojian Pharmaceutical. According to COO and chief business exec Stephan Lensky, a Boehringer Ingelheim vet, Chengbin Wu has been working on a bispecific antibody platform. And his old boss at Abbott, Robert Kamen, sits on the board. Kamen was the interim tech chief at Jounce Therapeutics when it launched and is an entrepreneur-in-resident at Third Rock, which is not involved in this round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
